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Background: Reoperative carotid endarterectomy (CEA) is an accepted treatment for recurrent carotid stenosis. With
reports of a higher operative morbidity than primary CEA and the advent of carotid stenting, catheter-based therapy has
been advocated as the primary treatment for this reportedly “high-risk” subgroup. This study reviews a contemporary
experience with reoperative CEA to validate the high-risk categorization of these patients.
Methods: From 1989 to 2002, 153 consecutive, isolated (excluding CEA/coronary artery bypass graft and carotid bypass
operations) reoperative CEA procedures were reviewed. Clinical and demographic variables potentially associated with
the end points of perioperative morbidity, long-term durability, and late survival were assessed with multivariate analysis.
Results: There were 153 reoperative CEA procedures in 145 patients (56% men, 36% symptomatic) with an average age
of 69  1.3 years. The average time from primary CEA (68% primary closure, 23% prosthetic, 9% vein patch) to
reoperative CEA was 6.1  0.4 years (range, 0.3 to 20.4 years). At reoperation, patch reconstruction was undertaken in
93% of cases. The perioperative stroke rate was 1.9%, with no deaths or cardiac complications. Other complications
included cranial nerve injury (1.3%) and hematoma (3.2%). Average follow-up after reoperative CEA was 4.4 0.3 years
(range, 0.1 to 12.7 years), with an overall total stroke-free rate of 96% and a restenosis rate (>50%) by carotid duplex of
9.2%. Among variables assessed for association with restenosis after reoperative CEA, only younger age was found to be
significant (66  2.5 years vs 70  0.7 years, P < .05). The all-cause long-term mortality rate was 29%. Multivariate
analysis of long-term survival identified diabetes mellitus as having a negative impact (hazard ratio, 3.4  0.3, P < .05)
and lipid-lowering agents as having a protective effect (hazard ratio, 0.42  0.4, P < .05) on survival.
Conclusion: Reoperative CEA is a safe and durable procedure, comparable to reported standards for primary CEA, for
long-term protection from stroke. These data do not support the contention that patients who require reoperative CEA
constitute a “high-risk” subgroup in whom reoperative therapy should be avoided. (J Vasc Surg 2005;41:942-9.)Supported by level 1 evidence, carotid endarterectomy
(CEA) remains the gold standard compared to medical
therapy for stroke prevention in patients with both symp-
tomatic and asymptomatic flow-limiting stenosis of the
internal carotid artery.1-3 The surgical treatment of carotid
artery stenosis is predicated on both a low operative risk and
a durable reconstruction. The perioperative risk of CEA has
been well elucidated, and many contemporary series con-
tinue to affirm the safety of this operation.4,5 With the
advent of new treatment modalities such as carotid artery
stenting (CAS), efforts to define the specific subgroup who
might benefit from such alternative therapy have received
much attention.6-8
With respect to durability of CEA, several variables
have emerged such as patch reconstruction, renal function,
serum lipid profile, gender, and pharmacotherapy.9-11 Re-
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942stenosis can occur after CEA, and the patient progresses to
either symptomatic disease or severe recurrent stenosis. The
actual incidence of recurrent carotid stenosis is ill-defined
because of variable follow-up and diagnostic standards. In
addition, the natural history of recurrent stenosis may be
more benign than the primary atherosclerotic plaque, ow-
ing to the histologic differences.12
Although reoperative CEA is reported to be appropri-
ate for patients with significant restenosis,13-15 the need for
re-dissection of the prior operative field and other technical
hazards has led some to label these patients as “high-risk”.
Indeed, a literature exists that suggests local anatomic
complications such as cranial nerve injury occur more fre-
quently in these patients.16 Consequently, virtually every
CAS trial includes reoperative CEA among the high-risk
inclusion criteria. Towards this end, the recently published
Stenting and Angioplasty with Protection in Patients at
High Risk for Endarterectomy (SAPPHIRE) study has
documented the noninferiority of CAS versus CEA in a
high-risk subgroup of patients.6 This high-risk classifica-
tion, though supported in the literature, has been a subject
of continued debate.
The purpose of this study is to delineate the operative
risk, long-term durability, and stroke-free survival benefit
of reoperative CEA in a contemporary surgical series. This
is particularly timely with the advent of endovascular ther-
apies for carotid stenosis and the inclusion of patients with
recurrent carotid disease in the initial indication for CAS.
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Patient selection and data collection. The comput-
erized databases and medical records of the Massachusetts
General Hospital (retrospective), Vascular Surgery Regis-
try, and operative logs (prospective) were cross-referenced
to identify patients who underwent reoperative CEAs be-
tween January 1989 through December 2002 performed
by surgeons in the Division of Vascular and Endovascular
Surgery. Only isolated, reoperative CEAs were included in
the study; those performed with a bypass or in conjunction
with cardiac surgery were excluded from analysis. The
primary end points of this study included perioperative
complications and death, anatomic durability as defined by
duplex exam, and stroke-free survival. Patient longevity was
also examined as a secondary end point.
The temporal relationship from primary CEA and type
of reconstruction (patch or primary closure) was recorded.
Patient clinical and laboratory data, operative details, post-
operative carotid noninvasive studies, and clinical course
for those undergoing reoperative CEA were recorded. A
clinical criteria determination was made at the time of
reoperative CEA, and their definitions are:
● hypertension: taking antihypertensive medication,
consistent blood pressure 150 mm Hg systolic or
90 mm Hg diastolic;
● diabetes mellitus: receiving insulin, oral hypoglycemic
medication, or having two serum blood glucose values
150 mg/dL;
● coronary artery disease: history of myocardial infarc-
tion, congestive heart failure, coronary artery bypass
graft or intervention, symptoms of angina, or identifi-
cation of a positive stress test, and
● chronic obstructive pulmonary disease: routine use of
inhalers or symptoms of lifestyle limiting dyspnea.
In addition, the use of lipid-reduction pharmacother-
apy was recorded. The laboratory values used were those at
the time of reoperative surgery.
Operative procedure. Operative procedures were
performed under general anesthesia with electroencephalo-
graphic monitoring and selective shunting. During the
study period, all CEAs were performed by longitudinal
arteriotomy through the common and internal carotid
arteries. Venous or prosthetic patches for the closure of the
carotid artery were used selectively. Intraoperative assess-
ment of the reconstruction was done by continuous wave
Doppler ultrasound scanning.
Perioperative outcome. End points in this study in-
cluded perioperative (30 day) complications and patient
longevity. Hospital and patient office records were screened
for any adverse event during the hospitalization that was
associated with the surgical procedure. Particular impor-
tance was afforded to postoperative cardiovascular and
neurologic status as documented in the record. For the
purpose of this study, a perioperative stroke was defined as
a central neurologic deficit ipsilateral to the operative side.Recurrent (tertiary) stenosis. Postoperative outpa-
tient follow-up was generally within 6 weeks with carotid
duplex ultrasound of the operative site. Follow-up contin-
ued at least to 2 years, unless evidence of carotid restenosis
developed. Any abnormal finding consistent with a stenosis
of50% (internal-to-common carotid artery ratio2.0 or
an internal carotid artery end-diastolic velocity 100
cm/s) was considered recurrent disease. In addition, pro-
gression to 75% stenosis (internal to common carotid
artery ratio 4.0 or an internal carotid artery end diastolic
velocity 140 cm/s), total occlusion, or the need for
subsequent reoperation was considered anatomic failure. A
final measure of durability was assessed via the occurrence
of a cerebrovascular event associated with the operative
side.
Long-term outcome. Patient medical records were
searched longitudinally for evidence of stroke, recurrent
symptoms, or death. When patient long-term follow-up
was lacking, it was supplemented by direct telephone con-
tact with the patient. For patients who lacked recent clinical
data and could not be reached, the date and causes of death
were requested and procured from the National Death
Index in Bethesda, Md. These data were used to determine
overall longevity and stroke-free survival.
Data analysis. The effect of variables on the develop-
ment of recurrent stenosis and stroke were examined with
univariate methods (2 or Student’s t test as appropriate).
With the exception of age, time from primary CEA, serum
cholesterol, and clinical variables were dichotomized. To
identify variables associated with the development of recur-
rent carotid disease requiring reoperation, a previously
described database was used.17 A multivariate descending
logistic analysis was done to examine clinical differences at
the time of the primary CEA that were associated with the
need for eventual reoperation. Life-table techniques were
used to calculate stroke-free survival and total survival for
the reoperative population. Clinical variables that impact
total survival were determined by multivariate analysis with
the Cox hazard ratio (HR). The analysis was generated
using Statistical Analysis System (SAS) software (SAS Insti-
tute Inc., Cary, NC).
The protocols of this study were independently re-
viewed and approved by the institutional human study
committee. In addition, the review board of the National
Death Index in Bethesda, Md approved the protocol for
release of the patient data.
RESULTS
Patient and operative profile. During the 14-year
study period, 145 patients underwent 153 reoperative ca-
rotid endarterectomies (Tables I and II). Only two opera-
tions were performed for tertiary restenosis. Details of the
primary CEA indicate that 32% had patch closure, and the
average time from primary CEA to reoperation was 6.1 
0.4 years. The temporal relationship from primary CEA and
indication is shown in Fig 1. With respect to operative
indication (symptoms), no difference was noted between
early (2 years from primary CEA, 41% of patients) and
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reconstruction was used in 93% of cases.
Analysis of factors associated with reoperative
CEA. A database that has previously been described13 was
used to construct a multivariate model to examine variables
associated with the requirement for reoperative CEA (Ta-
ble III). A total of 2,065 endarterectomies were compared
to the 153 in the current study, and hypertension was
identified as a significant deleterious variable (odds ratio
[OR], 2.8; 95% CI, 1.5 to 5.2; P .01) and use of a patch
at primary CEA was protective (OR, 0.7; 95% CI, 0.5 to
0.9; P  .05). Age, gender, diabetes mellitus, coronary
disease, smoking history, and lipid profile did not have a
Table I. Patient characteristics
n %
Demographics
Patients 145 100
Age 69.9  0.7
Female gender 61 41.8
Symptoms 53 36.3
TMB 25 17.1
TIA 18 12.3
Stroke 10 6.9
Clinical
Diabetes mellitus 30 20.9
CAD 78 53.8
Hypertension 134 91.8
Hyperlipidemia 105 71.9
COPD 19 13.0
Tobacco (any history) 102 70.3
Lipid-lowering therapy 85 58.2
Cholesterol (mg/dL) 199.3  4.1
TMB, Transient monocular blindness; TIA, transient ischemic attack;CAD,
coronary artery disease; COPD, chronic obstructive pulmonary disease.
Table II. Surgical characteristics of 153 reoperative
carotid endarterectomies
n %
General
Total cases 153 100
Contralateral CEA 61 39.9
Time from CEA (yrs) 6.1  0.4
Patch at first CEA 49 32
Imaging
Angiography 73 47.7
Computed tomography 10 6.6
Magnetic resonance 34 22.5
Operative
General anesthesia 153 100
EEG monitoring 145 94.7
Shunt 39 25.4
Patch reconstruction 143 93.5
Dacron 79 51.6
ePTFE 8 5.2
Vein 56 36.6
CEA, Carotid endarterectomy; EEG, electroencephalography; ePTFE, ex-
panded polytetrafluoroethylene.significant influence on the requisite for reoperative CEA.Morbidity and mortality. True 30-day data was
available for 140 (96.5%) of the 145 patients; in-hospital
perioperative data were used for the remaining five patients.
Three strokes occurred in the study patients: two post-
operative and one after diagnostic angiography. The two
postoperative strokes resulted in one hemiparesis and one
functionally minor hand weakness, whereas the postan-
giography stroke left the patient with a decreased dorsiflex-
ion of the affected foot.
Cranial nerve injury was seen in only two patients
(1.3%); one was a permanent hypoglossal nerve injury, the
other a transient facial droop and minor tongue deviation.
Significant wound hematoma occurred in five (3.2%),
with four patients requiring reoperation.
The total stroke and death rate was 1.9%, with no
perioperative mortality or cardiac events (Table IV). The
all-cause mortality (early and late) was 28.7%, and the
total stroke rate (early and late) was 3.9% over an average
follow-up of 4.4  0.2 years.
Secondary restenosis and stroke. Fourteen cases of
restenosis (50%) were seen, with two cases of anatomic
failure (75%) over an average 4.4-year follow-up period
(Table IV). Duplex follow-up of 2 years was available for
122 patients (84.5%). Univariate analysis for restenosis after
reoperative CEA or anatomic failure is summarized in
Table V. Of the patient and surgical variables examined,
only patient age was inversely associated with restenosis
(66.1  0.3 years vs 70.0  0.7 years, P  .05). None of
the other comorbidities examined approached statistical
significance. Statistical analysis was also undertaken to ex-
amine the role of patient and operative factors on the
development of either early or late ipsilateral stroke, and no
Fig 1. Histogram of time from index carotid endarterectomy
(CEA) to reoperative CEA. Indication for reoperation: symptom-
atic (black) and asymptomatic restenosis (grey).significant variables were identified.
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sis techniques were used to examine total survival and
stroke-free survival for the study population (Figs 2 and 3).
Five- and 10-year survival was 74%  5% and 42%  8%,
with a stroke-free survival at the same time points of 96%
3% and 95%  4%. Multivariate analysis was undertaken to
examine the role of both patient and surgical variables on
total survival (Table VI). This demonstrated a significant
deleterious effect with advancing age (HR, 1.1  0.02 per
year; P .05), the presence of diabetes mellitus (HR, 3.4
0.4; P  .01) and a protective effect of lipid-reduction
pharmacotherapy (HR, 0.4  0.4, P  .01).
DISCUSSION
Reoperative CEA has been affirmed by many as a safe
and durable procedure.13-15 Several studies have docu-
mented a low perioperative procedural risk with good
durability. However, with the emerging field of extracranial
catheter-based therapies, these results have been ques-
Table III. Multivariate analysis of variables associated
with progression to reoperative carotid endarterectomy
OR 95% CI P
Patient variables
Age (yrs) 0.996 0.983-1.009 .52
Female gender 1.309 0.922-1.858 .13
Diabetes mellitus 0.769 0.505-1.170 .22
Coronary artery disease 0.846 0.599-1.193 .34
Hypertension 2.878 1.574-5.262 .0006*
Hyperlipidemia 0.704 0.432-1.150 .16
COPD 1.037 0.620-1.734 .89
Tobacco 1.035 0.709-1.510 .86
Lipid-lowering therapy 1.383 0.948-2.017 .092
Operative variables
Patch reconstruction 0.664 0.471–0.937 .019†
OR, Odds ratio; CI, confidence interval; COPD, chronic obstructive pul-
monary disease.
*P  .01.
†P  .05.
Table IV. Perioperative and long-term outcomes after
reoperative carotid endarterectomy
n %
Perioperative
Stroke 3 1.9
Mortality 0 0
Myocardial infarction 0 0
Hematoma/bleeding 5 3.2
Nerve injury 2 1.3
Other 3 1.9
Durability
Restenosis 14 9.1
Anatomic failure 2 1.3
Total (short and long-term)
Stroke 6 3.9
Mortality 44 28.7tioned. Damage to nearby anatomic structures is com-monly cited as a reason to avoid reoperative surgery in the
setting of secondary stenosis. Also, the recurrent lesion may
represent a lower risk compared with primary carotid dis-
ease, owing to its histologic features.12 In addition, it can
be hypothesized that patients with recurrent carotid disease
may represent a high-risk cohort because they have dem-
onstrated a propensity for the development of atheroscle-
rotic disease that may be translated to other vascular
beds.18,19 This study was undertaken to evaluate both the
perioperative risk inherent to reoperative CEA and the
durability of this secondary procedure in the context of
minimally invasive approaches to recurrent cerebrovascular
disease.
The average time from the first CEA was 6.1  0.4
years, with 36% demonstrating symptoms with their recur-
rent disease. As demonstrated by others, this study showed
an asymmetric temporal distribution, with 41% of the cases
occurring within 2 years of the primary CEA. The timing of
restenosis is of biologic importance, with early (2 years)
cases being consistent with myointimal hyperplasia and late
(2 years) recurrence generally ascribed to atherosclerotic
disease.12,14 In this study, time from primary CEA did not
have an impact on perioperative complications, develop-
ment of stroke, or patient longevity. In addition, we were
unable to identify any cases of residual disease in the current
study.
At the primary CEA (many done at other institutions),
most patients underwent primary closure of the carotid
arteriotomy. During the same period, patch closure was
used in about half of our primary CEA cases (52% vs
32%).17 Many of the reoperative cases in the current series
were referred to our institution, thus it is impossible to
know how many patients with primary closure done at
other hospitals did not develop recurrent disease or how
many of the carotid reconstructions had residual disease
after operative intervention.
However, the multivariate analysis comparing primary
CEA cases progressing to reoperation with those not re-
quiring further intervention confirmed the benefit of patch
reconstruction. Indeed, several prospective trials have dem-
onstrated the protective effects of patch angioplasty, and
most consider patch closure the preferred technique.11 In
this current study, a subset analysis failed to delineate
differences based on type of patch closure at primary CEA.
In addition, we identified hypertension as a variable
associated with reoperative CEA (80% in those not pro-
ceeding to reoperation, 92% in those requiring reopera-
tion), demonstrated also by others.20-22 The relatively high
percentage of patients with hypertension and cerebrovas-
cular disease makes this association of limited value, but
does suggest the importance of blood pressure control after
CEA.
Although implicated by other authors, this study did
not demonstrate a significant relationship between gender,
tobacco, diabetes mellitus, or lipid profile and progression
to reoperative CEA. Many of these variables may indeed
impact disease progression, but for this cohort of patients,
there was no impact on the eventual requirement for reop-
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the negative impact of female gender, renal insufficiency,
primary closure, and a protective effect of lipid-lowering
agents on the development of restenosis.9 These discrepan-
cies with the present study may be ascribed simply to
sample size, temporal collection of the patient cohort, or
may be related to the more ambiguous nature of recurrent
Table V. Univariate analysis of patient and surgical variab
Any Restenosis
Yes (%) No (%)
Patient variables
Number 14 139
Age (yrs) 66.1  0.3* 70.0  0.7
Female gender 9 (64) 56 (40.3)
Diabetes mellitus 2 (14.2) 28(20.6)
CAD 8 (57.1) 74 (53.6)
Hypertension 12 (85.7) 129 (91.3)
Hyperlipidemia 13 (92.8) 99 (71.2)
COPD 0 (0) 20 (14.4)
Tobacco 8 (61.7) 99 (71.2)
Lipid-lowering therapy 12 (85.7) 78 (56.1)
Cholesterol (mg/dL) 199.2  11.4 200.2  4.4
Time from primary
CEA (yrs)
5.9  1.4 6.3  0.4
Operative variables
Symptomatic 5 (35.7) 50 (35.9)
Shunt 4 (28.6) 35 (25.2)
Patch reconstruction 12 (85.7) 131 (94.2)
CAD, Coronary artery disease; COPD, chronic obstructive pulmonary dise
*P  .05.
†P  .01.
Fig 2. Kaplan-Meier curve demonstrates stroke-free survival in
the study population as measured from the date of reoperative
carotid endarterectomy (CEA) (broken line shows standard error).carotid disease and the clinical indications for reoperation.Periprocedural morbidity in this series is comparable to
our larger report of primary CEA.17 Guidelines suggested
by the American Heart Association define an acceptable
stroke/death rate of 6% for symptomatic patients, and
3% for asymptomatic patients.23 Although these guide-
sociated with subsequent restenosis or stroke
Anatomic Failure Stroke
Yes (%) No (%) Yes (%) No (%)
2 151 6 147
9.9  0.7 67.9  2.2 69.9  3.6 69.1  1.0
(100) 63 (41) 4 (66.7) 61 (41.5)
(0) 30 (20) 3 (50) 27 (18.8)
(50) 81 (54) 2 (33.3) 80 (54.8)
(100) 139 (92) 6 (100) 135 (91.8)
(100) 110 (72) 3 (50) 109 (74.2)
(0) 20 (13) 1 (16.6) 19 (12.9)
(100) 105 (70) 5 (83.3) 102 (69.4)
(100) 88 (58) 2 (33.3) 88 (59.9)
6.5  9.5 197.7  4.1 197.8  19.8 205.5  3.8
2.5  4.5 6.1  0.4 6.2  2.4 4.6  0.3
(50) 54 (35) 4 (66.7) 51 (34.7)
(50) 38 (25) 1 (16.6) 38 (25.8)
(0)† 143 (94) 6 (100) 137 (93.2)
EA, carotid endarterectomy.
Fig 3. Kaplan-Meier curve demonstrates total survival in the
study population as measured from the date of reoperative carotid
endarterectomy (CEA) (broken line shows standard error).les as
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ase; Clines are intended for primary CEA, another consensus
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death rate for reoperative CEA to be 10%.24
In addition, there was no evidence of postoperative
myocardial infarction in these patients, albeit routine
screening with electrocardiography or cardiac enzyme assay
was not done unless clinically indicated.
The low rate of major adverse outcome in this study is
echoed by other reoperative series, with stroke/death rates
noted between 0% and 7%.14,25-30 The neck hematoma rate
was 5%, again consistent with previously published and
acceptable rates as defined by the randomized trials.1,23
The two cases of nerve injury seen in this study (3.2%)
are also well within cited guidelines for primary CEA and
demonstrate that meticulous technique can yield excellent
results, despite the presence of a reoperative field.31 How-
ever, others have demonstrated that with formal neurologic
evaluation, including direct laryngoscopy, a much higher
cranial nerve injury rate is observed.16 Although most of
these are transient and without clinical significance, it is
quite possible that with independent otolaryngology eval-
uation, the rate of cranial nerve injury would have been
higher in this study.
This study defined any restenosis after reoperative CEA
as a duplex examination documenting restenosis of 50%.
There were 14 cases of any restenosis (9.1%) incidence
throughout an average follow-up of 4.4 0.2 years. None
of these patients went on to require tertiary reoperation or
intervention nor did they have a stroke.
Univariate analysis demonstrated that secondary re-
stenosis tended to occur in younger patients, but no
other covariates were identified. Younger patients were
more likely to develop subsequent restenosis, which
suggests that this cohort of patients may have innate
differences in their vascular biology and mandates close
Table VI. Multivariate analysis of variables associated
with all-cause mortality
Hazard ratio P
Patient variables
Age (years) 1.053  0.02 .017*
Female gender 0.826  0.38 .61
Diabetes mellitus 3.439  0.38 .0018†
Coronary artery disease 1.311  0.35 .44
Hypertension 0.453  0.57 .16
Hyperlipidemia 0.754  0.45 .53
COPD 0.919  0.46 .85
Tobacco 1.049  0.30 .88
Lipid-lowering therapy 0.423  0.38 .026*
2 years from primary CEA 0.492  0.40 .078
Operative variables
Symptomatic 0.881  0.35 .71
Shunt 1.598  0.37 .21
Patch reconstruction 1.111  0.64 .87
COPD, Chronic obstructive pulmonary disease; CEA, carotid endarterec-
tomy.
*P .05.
†P .01.postprocedure follow-up.Using a more stringent criterion for anatomic failure
(75% stenosis or occlusion), we identified only two cases.
Univariate analysis demonstrated use of patch angioplasty
as the only significant variable influencing the development
of failure after reoperative CEA. Although the small num-
ber of cases makes this analysis difficult, it does again
suggest the protective effects of patch reconstruction for
anatomic durability. Patch closure of the carotid arteriot-
omy was used in almost all of the reoperative cases in this
study.
Stroke-free survival must be considered the ultimate
measure of operative durability. The study population had
six strokes (three perioperative and three long-term). The
stroke-free survival by life-table analysis at 5 and 10 years
was 96% and 95% respectively, thus demonstrating excel-
lent clinical effectiveness from repeat CEA. Other authors,
also demonstrating a strong ipsilateral stroke-risk reduction
in patients undergoing reoperative CEA, have reported
similar results.32 The present study did not do formal
neurologic testing and, therefore, most likely underesti-
mates the true incidence of stroke.
A second consideration for the cohort of patients de-
veloping recurrent carotid stenosis is their expected longev-
ity. Clearly, many patients with recurrent disease are dis-
playing a predilection towards aggressive arteriosclerosis,
and carotid disease can be seen as a marker for this systemic
process. By life-table analysis, the total survival at 5 and 10
years from reoperation was 74% and 42%. Multivariate
analysis demonstrated several important variables that in-
fluence this survival.
First, age was an obvious factor, with chronologic age
at the time of reoperation having a negative impact on
survival. This finding raises the question of reoperative
surgery in patients with advanced age. In fact, some authors
have used operative risk and expected longevity to ques-
tioned the role of CEA in the octogeneraian.33,34 An
assessment of expected perioperative risk coupled with
expected longevity is a requisite.
Diabetes mellitus is another significant variable that has
been well documented as an independent risk factor for the
development of cardiovascular-related adverse events, and
subsequent survivial.35,36
Finally, the use of a lipid-lowering agent during the
postoperative period had a significant positive impact on
survival. This finding was independent of the serum lipid
profile, and in fact, hyperlipidemia was not found to be a
significant predictor in the multivariate analysis. Population
based studies have demonstrated a marked reduction in
all-cause mortality and cardiovascular risk in patients
treated with lipid-lowering agents.37,38
In addition, HMG-CoA reductase inhibitors have been
found to have a pleiotropic effect both in vitro and in vivo,
and through this presumptive action are able to influence
the remodeling of atherosclerotic disease in a variety of
vascular beds.39,40 In the current study, the presence of
lipid-lowering pharmacotherapy was found to be protec-
tive, and illustrates a point of intervention that must be
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ported of all CEAs.9
Some authors have suggested catheter-based interven-
tions for patients with recurrent disease. The proposed
benefit is a lower procedural cardiovascular risk coupled
with the complete avoidance of cranial nerve injury. Fur-
thermore, it can be argued that stenting in the setting of
myointimal hyperplasia has far less potential for atheroem-
bolic complications. Despite these concerns, no myocardial
infarctions or deaths occurred in this series after redo CEA.
In addition, only one permanent cranial nerve injury was
identified, demonstrating that reoperative CEA can be
undertaken safely. In fact, recent data suggests that al-
though there is essentially no risk for cranial nerve injury
with carotid artery stenting, the risk for restenosis com-
pared with surgically treated patients to be increased.41
Many variables will influence the choice of therapy
for recurrent carotid stenosis; important among these is
surgical experience and expertise. A valid criticism of the
present study can be the objection as to whether these
results can be achieved across a broad spectrum of sur-
geons and practice settings. Such questions are difficult
to answer, but these results are similar to other reopera-
tive CEA series.13-15,21,25,27-29
In summary, these data do not support the contention
that patients with recurrent carotid disease constitute a
high-risk population of patients for whom stenting should
be considered initial therapy. Clearly, this proposition will
only be definitively answered in the future by results of
comparative clinical trials.
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Despite being the most evidence-based procedure in surgical
history, carotid endarterectomy (CEA) maintains an unparalleled
reputation for controversy, none more so than the management of
recurrent stenosis. In the United Kingdom and Scandinavia, few
advocate intervention for recurrent stenosis unless the patient is
symptomatic. However, in mainland Europe and the United
States, there is a totally opposing viewpoint. Here the only debate
is whether treatment should be surgical or interventional. How is it
possible that the same scientific literature can be interpreted in such
a polarized way?
The paper by Stoner et al is typical of supporters of redo
surgery in its fundamental assumption that an asymptomatic, re-
current stenosis (ie, neointimal hyperplasia) confers an equivalent
stroke risk to atherosclerotic lesions. (Astute readers will have
observed, however, that Stoner et al did not have the same over-
whelming need to intervene on the 14 patients who developed
recurrent stenoses after redo surgery and who remained com-
pletely asymptomatic!) Thereafter, practice is usually justified by
the results of the Asymptomatic Carotid Atherosclerosis Study
(ACAS) and Asymptomatic Carotid Surgery Trial (ACST).1,2 This
is reflected by the authors’ comments that “reoperative CEA is an
accepted treatment for recurrent stenosis” and “reoperative CEA
has been affirmed as a safe and durable procedure.”Do these claims
stand up to close scrutiny? Are the authors’ results generalizable to
routine clinical practice?
Notwithstanding the inevitable problems associated with ret-
rospective studies (apparently no one lost to follow-up despite
some living far away, no clinical cardiac events, no data on patients
with recurrent stenoses not subjected to surgery, only two cranial
nerve injuries identified, and a nonstandard definition of perioper-
ative stroke), the principle results are extremely good and the
authors are to be commended. In this particular surgical unit, it
would be wrong to say that a policy of redo surgery was inappro-
priate in the face of a 1.9% complication rate.
However, I suspect that this very low level of risk, which is less
than that observed after primary CEA in ACAS and ACST, is
unlikely to be typical of overall clinical practice, and this observa-
tion is supported by the latest multistate audit by Kresowik et al.3
In the Kresowik et al series of 401 contemporary, redo CEAs in 10
states in the United States, the risk of perioperative death and
stroke was 5.7%. If this is a true reflection of practice—and it
probably is—and one assumes that the natural history (stroke risk)
of patients with recurrent disease is similar to that of asymptomatic
atherosclerotic patients, a simple reworking of the ACAS databy operating on 1,000 patients with restenosis where the periop-
erative risk is 5.7%.
Similarly, Stoner et al acknowledged the emergence of angio-
plasty as an alternative to redo CEA and cited the Stenting and
Angioplasty with Protection in Patients at High Risk for Endarter-
ectomy (SAPPHIRE) trial as showing noninferiority between the
two treatment strategies.4 In fact, 78% of SAPPHIRE patients
were asymptomatic (many were recurrent stenoses) in whom the
procedural risk averaged almost 6% for both treatment limbs. As
with the Kresowik et al study, this is a level of risk where there is no
natural history evidence that any intervention is warranted at all!
In summary, vascular units with results comparable to that of
Stoner et al can quite easily justify treating patients with recurrent
stenosis after CEA. However, those with complication rates 4%
cannot simply extrapolate the ACAS or ACST data to justify
intervention in patients with asymptomatic recurrent stenoses after
CEA. This statement clearly questions whether existing American
Heart Association (AHA) Guidelines should still apply. As Stoner
et al noted, the AHA advises surgeons that the stroke risk after
surgery for recurrent stenosis should be 10%.5 If we assume that
medically treated patients in ACAS and ACST do represent the
true natural history risk for patients with asymptomatic, recurrent
disease—which remains a generous assumption—surgeons per-
forming redo CEA with a 10% stroke risk will cause approximately
20 more strokes per 1,000 redo CEAs at 5 years than would have
occurred if patients had been left on medical treatment alone.
Stoner et al are to be commended for their results, but national
guidelines need to be revised.
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